open access

Vol 80, No 12 (2022)
Expert opinion
Get Citation

The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society

Marcin Wełnicki1, Iwona Gorczyca-Głowacka2, Artur Mamcarz1, Krzysztof J Filipiak3, Beata Wożakowska-Kapłon24, Marcin Barylski5, Filip M Szymański6, Jarosław D Kasprzak7, Marcin Grabowski8, Grzegorz Dzida9
DOI: 10.33963/KP.a2022.0282
·
Pubmed: 36601885
·
Kardiol Pol 2022;80(12):1286-1289.
Affiliations
  1. 3rd Department of Internal Diseases and Cardiology, Medical University of Warsaw, Warszawa, Poland
  2. Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland
  3. Institute of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warszawa, Poland
  4. 1st Department of Cardiology and Electrotherapy, Świętokrzyskie Cardiology Center, Kielce, Poland
  5. Department of Internal Diseases and Cardiac Rehabilitation, Medical University of Lodz, Łódź, Poland
  6. Departament of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, Warszawa, Poland
  7. 1st Chair and Department of Cardiology, Medical University of Lodz, Łódź, Poland
  8. 1st Chair and Department of Cardiology, Medical University of Warsaw, Warszawa, Poland
  9. Department of Internal Diseases, Medical University of Lublin, Lublin, Poland

open access

Vol 80, No 12 (2022)
Expert opinion and position paper

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 80, No 12 (2022)

Article type

Expert opinion

Pages

1286-1289

Page views

560

Article views/downloads

121

DOI

10.33963/KP.a2022.0282

Pubmed

36601885

Bibliographic record

Kardiol Pol 2022;80(12):1286-1289.

Authors

Marcin Wełnicki
Iwona Gorczyca-Głowacka
Artur Mamcarz
Krzysztof J Filipiak
Beata Wożakowska-Kapłon
Marcin Barylski
Filip M Szymański
Jarosław D Kasprzak
Marcin Grabowski
Grzegorz Dzida

References (72)
  1. Fowler M. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008; 26(2): 77–82.
  2. IDF Diabetes Atlas, 10th edition. Available from: https://diabetesatlas.org/atlas/tenth-edition/. [Accessed: June 21, 2022].
  3. Mortality and deaths by causes. Statistics Poland. Available from: https://stat.gov.pl/obszary-tematyczne/ludnosc/statystyka-przyczyn-zgonow/. [Accessed: June 21, 2022].
  4. Shah S, Feher M, McGovern A, et al. Diabetic retinopathy in newly diagnosed Type 2 diabetes mellitus: Prevalence and predictors of progression; a national primary network study. Diabetes Res Clin Pract. 2021; 175: 108776.
  5. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28(1): 164–176.
  6. Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneap Minn). 2014; 20(5 Peripheral Nervous System Disorders): 1226–1240.
  7. Tavares CA, Wajchjenberg BL, Rochitte C, et al. Screening for asymptomatic coronary artery disease in patients with type 2 diabetes mellitus. Arch Endocrinol Metab. 2016; 60(2): 143–151.
  8. Connelly KA, Gilbert RE, Liu P. Treatment of diabetes in people with heart failure. Can J Diabetes. 2018; 42 Suppl 1: S196–S200.
  9. Beckman JA, Creager MA. Vascular complications of diabetes. Circ Res. 2016; 118(11): 1771–1785.
  10. Laakso M, Kuusisto J. Cerebrovascular disease in type 2 diabetes. International Congress Series. 2007; 1303: 65–69.
  11. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  12. Rakipovski G, Rolin B, Nøhr J, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018; 3(6): 844–857.
  13. Schernthaner G, Shehadeh N, Ametov AS, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020; 19(1): 185.
  14. Wilcox T, De Block C, Schwartzbard AZ, et al. Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar. J Am Coll Cardiol. 2020; 75(16): 1956–1974.
  15. Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetol. 2011; 54(1): 10–18.
  16. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3): 153–165.
  17. Drucker D, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet. 2006; 368(9548): 1696–1705.
  18. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373(1): 11–22.
  19. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17(6): 819–837.
  20. Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity (Silver Spring). 2015; 23(6): 1119–1129.
  21. Hogan AE, Gaoatswe G, Lynch L, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetol. 2014; 57(4): 781–784.
  22. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014; 124(10): 4223–4226.
  23. Bagger JI, Holst JJ, Hartmann B, et al. Effect of oxyntomodulin, glucagon, GLP-1, and combined glucagon +GLP-1 infusion on food intake, appetite, and resting energy expenditure. J Clin Endocrinol Metab. 2015; 100(12): 4541–4552.
  24. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998; 101(3): 515–520.
  25. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; 19(9): 1242–1251.
  26. Tong J, D'Alessio D. Give the receptor a brake: slowing gastric emptying by GLP-1. Diabetes. 2014; 63(2): 407–409.
  27. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016; 64(2): 399–408.
  28. Armstrong M, Gaunt P, Aithal G, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet. 2016; 387(10019): 679–690.
  29. Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017; 13(10): 605–628.
  30. Bydureon Summary of Product Characteristics.
  31. Lyxumia®. Summary of Product Characteristics.
  32. Victoza®. Summary of Product Characteristics.
  33. Ozempic. Summary of Product Characteristics.
  34. Rybelsus. Summary of Product Characteristics.
  35. Trulicity™. Summary of Product Characteristics.
  36. Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014; 25(5): 407–414.
  37. Gallwitz B. Glucagon-like peptide-1 receptor agonists. JCD. 2016; 2: 31–43.
  38. Andersen A, Knop FK, Vilsbøll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs. 2021; 81(9): 1003–1030.
  39. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, et al. Clinical recommendations for the management of patients with diabetes 2021. The Position Statement of the Polish Diabetes Society. Curr Top Diabetes. 2022; 2(1): 1–134.
  40. Standards of Medical Care in Diabetes — 2022. Abridged for Primary Care Providers. Clinical Diabetes. 2022; 40(1): 10–38.
  41. Grant PJ, Cosentino F, Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
  42. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020; 42(14): 1289–1367.
  43. Nauck M, Rizzo M, Johnson A, et al. Once-Daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial. Diabetes Care. 2016; 39(9): 1501–1509.
  44. Buse J, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013; 381(9861): 117–124.
  45. Dungan K, Povedano S, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951): 1349–1357.
  46. Sorli C, Harashima Si, Tsoukas G, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5(4): 251–260.
  47. Ahrén Bo, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017; 5(5): 341–354.
  48. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018; 41(2): 258–266.
  49. Aroda V, Bain S, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5(5): 355–366.
  50. Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial. J Clin Endocrinol Metab. 2018; 103(6): 2291–2301.
  51. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834–1844.
  52. Pratley R, Aroda V, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6(4): 275–286.
  53. Lingvay I, Catarig AM, Frias J, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019; 7(11): 834–844.
  54. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol . 2019; 7(5): 356–367.
  55. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020; 46(2): 100–109.
  56. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019; 42(9): 1724–1732.
  57. Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care. 2019; 42(12): 2272–2281.
  58. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial. JAMA. 2019; 321(15): 1466–1480.
  59. Pratley R, Amod A, Hoff S, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019; 394(10192): 39–50.
  60. Mosenzon O, Blicher T, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019; 7(7): 515–527.
  61. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381(9): 841–851.
  62. Pieber T, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019; 7(7): 528–539.
  63. Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PIONEER 8 trial. Diabetes Care. 2019; 42(12): 2262–2271.
  64. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373(23): 2247–2257.
  65. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228–1239.
  66. Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Eng J Med. 2016; 375(4): 311–322.
  67. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193): 121–130.
  68. Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021; 46: 101102.
  69. Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab. 2017; 19(3): 336–347.
  70. Lorenz M, Lawson F, Owens D, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017; 16(1): 6.
  71. Aroda VR, Faurby M, Lophaven S, et al. Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. Diabetes Obes Metab. 2021; 23(9): 2177–2182.
  72. Sattar N, Lee M, Kristensen S, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021; 9(10): 653–662.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl